The report “HLA Typing Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Reagent, Software), Application (Chimerism, Antibody Screening), End User (Hospital, Diagnolab, Academia) & Region – Global Forecast to 2028″, is projected to reach USD 2.1 billion by 2028 from an estimated value of USD 1.4 billion in 2022, at a CAGR of 6.5% during the forecast period. The HLA typing market is mainly driven by rising incidence of neurovascular diseases, availability of medical reimbursements for neurovascular procedures, expansion of healthcare infrastructure across emerging economies, increased focus of players on boosting the research in novel neurovascular devices, and growing demand for minimally invasive surgical procedures.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=39129877
The molecular assay technologies segment accounted for the largest share of 86.5% in 2022, by technology segment.
Based on technology, the HLA typing market is segmented into molecular assay technologies and non-molecular assay technologies. The molecular assay technologies segment accounted for the largest market share in 2022. The large share of the segment is attributed to the benefits of molecular assay technologies over non-molecular assays, such as low turnaround times, high procedural efficacy, multi-sample study capabilities, and real-time sample analysis.
Molecular assay techniques are used in HLA typing for applications such as donor-recipient cross-matching, cancer and autoimmune disease diagnostics, infectious disease diagnostics, and transfusion.
This market is segmented into PCR-based molecular assays and sequencing-based molecular assays. The growing demand for molecular assays is mainly attributed to their technological benefits over non-molecular assays, such as low turnaround times, high procedural efficacy, and real-time sample analysis. Other factors supporting market growth include growing applications in patient profiling, rising public-private investments for product development, and increasing evidence for the clinical efficacy of molecular assay techniques, coupled with rising technological advancements in molecular diagnostics (such as PCR and NGS).
The diagnostic applications segment is anticipated to register highest CAGR during the forecast period.
Based on application, the diagnostic applications market is segmented into Donor Recipient Cross Match, Cancer Diagnosis & Prevention, Infectious & Non-infectious disease testing, Transfusion Therapy and Others. The diagnostic applications segment accounted for the highest CAGR of 6.5% during the forecasr period . The diagnostic applications segment is also projected to grow at the highest CAGR during the forecast period owing to the rising technological advancements in molecular assay techniques; increasing adoption of molecular assays for pathogen testing in infectious and non-infectious disease testing; and the growing incidence of chronic and infectious diseases.
North America to dominate the global HLA Typing Market
Based on the region, the HLA Typing Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America accounted for the largest share of HLA Typing Market. The large share of North America can be attributed to the high adoption of HLA typing devices in the region, the strong presence of companies operating in the market, and the availability of significant R&D investments for product development.
Asia Pacific is expected to grow at the highest CAGR during the forecast period owing to the presence of a large target patient population, rising awareness on the advantages HLA typing, geographical expansion of players in region, and government initiatives to modernize & expand healthcare infrastructure.
Key Market Players
Major players in HLA Typing Market include Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (US), and bioMérieux S.A. (France). Other players in the market are Immucor, Inc. (US), Illumina, Inc. (US), Luminex Corporation (US), CareDx (US), Becton, Dickinson and Company (US), Hologic (US), GenDx (Netherlands), and Biofortuna (UK), among others.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=39129877
Recent Developments:
- In March 2023, BioRad received The company received AOAC International and AFNOR approval for its iQ-Check kits, which are used with the CFX Opus Deepwell Real-time PCR System
- In August 2022 Roche developed a new digital Light cycler system that helps determine a patient’s cancer.
- In May 2022, CareDx received CE marking for its AlloSeq HCT chimerism testing kit and AlloSeq HCT software. These AlloSeq are used in patients who have received Hematopoietic cell transplantation.
HLA Typing Market Advantages:
- Improved Organ Transplantation Success: Accurate HLA typing plays a critical role in organ transplantation. Matching the human leukocyte antigen (HLA) profile between the donor and recipient increases the chances of transplant success and reduces the risk of rejection. HLA typing enables precise matching, resulting in improved patient outcomes and increased transplant success rates.
- Enhanced Disease Diagnosis and Treatment: HLA typing is utilized in the diagnosis and treatment of various immune-related disorders, including autoimmune diseases, allergies, and certain cancers. By identifying specific HLA alleles associated with these conditions, healthcare professionals can tailor treatment plans and therapies to individual patients, resulting in more effective and personalized care.
- Advancement of Precision Medicine: The field of precision medicine aims to deliver targeted treatments based on an individual’s genetic makeup. HLA typing provides valuable information about an individual’s immune system and genetic variability, allowing for personalized treatment selection and dosing optimization. This approach reduces the likelihood of adverse reactions, improves treatment efficacy, and enhances overall patient care.
- Expansion of Transfusion Medicine: HLA typing is crucial in blood transfusion compatibility testing. Matching the HLA antigens between the donor and recipient minimizes the risk of transfusion reactions, ensuring safe and compatible blood transfusions. This advancement has improved the overall safety and success of transfusion medicine.
- Research and Scientific Advancements: HLA typing serves as a fundamental tool in immunological research, facilitating studies on disease associations, population genetics, and immune response variability. By analyzing HLA data, researchers can gain insights into disease mechanisms, population diversity, and immunogenetics, leading to a deeper understanding of human health and the development of new therapies.
- Rapid Technological Advancements: The HLA typing market benefits from ongoing technological advancements, such as next-generation sequencing (NGS), high-resolution molecular techniques, and advanced data analysis algorithms. These advancements enable faster, more accurate, and cost-effective HLA typing, making it accessible to a larger population and facilitating widespread adoption in clinical practice.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=39129877
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/hla-typing-market-39129877.html